Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social, Governance & Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News

News & Views

Latest News

Category: News

See all

Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients

News,

Telix, Eckert & Ziegler, and RefleXion Medical today announced a comprehensive collaboration agreement to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor...

Read more

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Clinical, Events, News,

Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 –...

Read more

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Events, News,

Read more

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

ASX, News,

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise...

Read more

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August...

Read more

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

Clinical, News,

Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), for the...

Read more

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

Clinical, News,

Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard...

Read more

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise...

Read more

First Patient Dosed in STARSTRUCK Study

Clinical, News,

Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt,...

Read more

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market...

Read more

Posts navigation

1 2 … 30

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au